Assessing the new and emerging treatments for atopic dermatitis

Lawrence F. Eichenfield, Sheila F. Friedlander, Eric Simpson, Alan D. Irvine

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.

Original languageEnglish (US)
Pages (from-to)92S-96S
JournalSeminars in Cutaneous Medicine and Surgery
Volume35
DOIs
StatePublished - Jun 1 2016

Fingerprint

Atopic Dermatitis
Cytokines
Type II Interleukin-4 Receptors
Immunoglobulin E
Phosphodiesterase 4 Inhibitors
Formyl Peptide Receptor
Phase III Clinical Trials
Th2 Cells
Innate Immunity
Monoclonal Antibodies
Antibodies
Therapeutics

Keywords

  • Atopic dermatitis
  • Crisaborole
  • Dupilumab
  • Interleukin inhibitors
  • Petrolatum
  • Skin barrier

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)
  • Dermatology

Cite this

Assessing the new and emerging treatments for atopic dermatitis. / Eichenfield, Lawrence F.; Friedlander, Sheila F.; Simpson, Eric; Irvine, Alan D.

In: Seminars in Cutaneous Medicine and Surgery, Vol. 35, 01.06.2016, p. 92S-96S.

Research output: Contribution to journalArticle

Eichenfield, Lawrence F. ; Friedlander, Sheila F. ; Simpson, Eric ; Irvine, Alan D. / Assessing the new and emerging treatments for atopic dermatitis. In: Seminars in Cutaneous Medicine and Surgery. 2016 ; Vol. 35. pp. 92S-96S.
@article{dd4a215a30b641eea757e6cf953e8ba0,
title = "Assessing the new and emerging treatments for atopic dermatitis",
abstract = "The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.",
keywords = "Atopic dermatitis, Crisaborole, Dupilumab, Interleukin inhibitors, Petrolatum, Skin barrier",
author = "Eichenfield, {Lawrence F.} and Friedlander, {Sheila F.} and Eric Simpson and Irvine, {Alan D.}",
year = "2016",
month = "6",
day = "1",
doi = "10.12788/j.sder.2016.043",
language = "English (US)",
volume = "35",
pages = "92S--96S",
journal = "Seminars in Cutaneous Medicine and Surgery",
issn = "1085-5629",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Assessing the new and emerging treatments for atopic dermatitis

AU - Eichenfield, Lawrence F.

AU - Friedlander, Sheila F.

AU - Simpson, Eric

AU - Irvine, Alan D.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.

AB - The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.

KW - Atopic dermatitis

KW - Crisaborole

KW - Dupilumab

KW - Interleukin inhibitors

KW - Petrolatum

KW - Skin barrier

UR - http://www.scopus.com/inward/record.url?scp=85014728974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014728974&partnerID=8YFLogxK

U2 - 10.12788/j.sder.2016.043

DO - 10.12788/j.sder.2016.043

M3 - Article

VL - 35

SP - 92S-96S

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

SN - 1085-5629

ER -